Altogether, it is tempting to speculate on the dual therapeutic benefit of TZF compounds: by interacting with Tau leading to microtubule remodeling, compounds 2 and particularly 9 could indirectly enhance p53 delivery to the nucleus, thereby reducing tumorigenesis; in tauopathies, our compounds could protect Tau from kinase-mediated phosphorylation and aggregation, particularly by Cdk5 and GSK3β, which also antagonize the pro-apoptotic function of p53. Here, GSK3B is linked to tauopathy.